Enjoy complimentary customisation on priority with our Enterprise License!
Hyperinsulinemia is a condition in which abnormally high levels of insulin circulate in the body. Insulin is a hormone produced by the pancreas to maintain the blood sugar levels in the body. Hyperinsulinemia is associated with metabolic syndromes such as hypertension, obesity, dyslipidemia, and glucose intolerance. Hyperinsulinemia is often caused due to insulin resistance, which means, the body does not respond correctly to insulin. This condition can further lead to high blood sugar levels as diabetes progresses, high blood pressure, high cholesterol, and reduced blood fat levels. Hyperinsulinemia is often associated with type 2 diabetes in adults. In neonates, congenital hyperinsulinemia can be observed from birth. Congenital hyperinsulinemia is often caused by mutations in genes that regulate the release of insulin, which is produced by beta cells in the pancreas. The severity of congenital hyperinsulinemia varies widely among affected individuals, even among the members of the same family. According to NIH report in 2018, congenital hyperinsulinemia affects approximately 1 in 50,000 newborns in the US. Consequently, the rising incidences of this condition is expected to boost the drug development for hyperinsulinemia in the next few years.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for hyperinsulinemia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hyperinsulinemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.
According to this pipeline analysis report, most of the molecules currently developed in the drug development for hyperinsulinemia are being developed as small molecules and most of these molecules are chemically manufactured active substances entering the cells easily due to their low molecular weight of less than 900 Daltons.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.